Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Executes $350K Promissory Note

NEW YORK (GenomeWeb) – CombiMatrix said recently in its Form 10-Q that it executed a secured promissory note for $350,000 bearing a 10 percent annual interest rate.

In its document filed with the US Securities and Exchange Commission, the company said that it executed the promissory note on May 20 with ACC Investment. The note is secured by certain laboratory equipment used in its microarray services business and will be payable over a 36-month period. As of June 30 the fair value of the note was about $312,000.

CombiMatrix recently reported that its second quarter revenues were up 29 percent year over year.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more